The GIP receptor component provides complementary metabolic effects: Enhanced insulin sensitivity through direct action on adipose tissue Improved lipid metabolism via GIP-mediated effects on fat storage and mobilization Synergistic appetite suppression through combined incretin receptor activation in the hypothalamus Potentially better tolerated GI profile as GIP may partially offset GLP-1-mediated nausea Key Pharmacological Differences# Weight Loss Efficacy# Liraglutide (SCALE Program)# The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015) was the pivotal trial for Saxenda approval: 3,731 adults without diabetes, liraglutide 3.0 mg daily for 56 weeks Mean weight loss: 8.0% (vs 2.6% placebo) 63.2% achieved 5% or more weight loss 33.1% achieved 10% or more weight loss Tirzepatide (SURMOUNT Program)# The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) established tirzepatide as a leading obesity treatment: 2,539 adults without diabetes, tirzepatide 5/10/15 mg weekly for 72 weeks Mean weight loss at 15 mg: 20.9% (vs 2.4% placebo) Mean weight loss at 10 mg: 21.4% Mean weight loss at 5 mg: 16.0% 63.2% achieved 20% or more weight loss at 15 mg Cross-Trial Comparison# While cross-trial comparisons have inherent limitations (different populations, durations, endpoints), the magnitude of difference is clear: Tirzepatide achieves approximately 2.8-fold greater mean weight loss, and the proportion reaching clinically meaningful thresholds is substantially higher across all categories
The consequence is muscle loss
Below are known side effects of semaglutide, which are primarily GI related
Zepbound and Wegovy are both effective weight loss options , but they work in different ways to achieve results
After the lead-in period, patients were randomized at Week 36 to continue ZEPBOUND or switch to placebo for 52 weeks
/assets/production/practices/dffa88faf9887b01856b18477151f6b695f51a4e/images/2751963.jpg)
